Shares of Tekmira Pharmaceuticals (Nasdaq: TKMR) have rocketed after the US Food and Drug Administration authorized Tekmira to provide its investigational drug TKM-Ebola for treatment under expanded access protocols to people with confirmed or suspected Ebola virus infections. The company’s shares were up 12.8% to $22.74 yesterday on the news.
Mark Murray, Tekmira's president and chief executive, said: “Today we are reporting that, working closely with regulators in the United States and Canada, we have established a framework for TKM-Ebola use in multiple patients. In the USA, the FDA has granted expanded access use of TKM-Ebola under our Investigational New Drug application (IND) and Health Canada has established a similar framework, both of which allow the use of our investigational therapeutic in more patients."
Ebola drug is ‘well-tolerated’
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze